French pharmaceutical company Sanofi has agreed to acquire US-based Blueprint Medicines Corporation for approximately $9.5 billion, including potential milestone payments, Reuters reports.
The acquisition is aimed at strengthening Sanofi’s presence in rare diseases and immunology and would mark one of the largest healthcare deals in Europe this year.
Under the terms of the agreement, Sanofi will pay $129 per share in cash for Blueprint. In addition to the cash offer, Blueprint shareholders will receive a contingent value right (CVR), which includes potential milestone payments totaling up to $6 per share. These payments are tied to the future development and regulatory progress of BLU-808, an experimental therapy currently in Blueprint’s pipeline.
Sanofi Chief Executive Officer Paul Hudson said the acquisition represents “a strategic step forward in our rare and immunology portfolios” and enhances the company’s ability to position itself as a global leader in immunology.
Blueprint Medicines specializes in the development of treatments for systemic mastocytosis, a rare and chronic immunological condition caused by the accumulation of abnormal mast cells in various organs. The company’s lead product, Ayvakit (marketed as Ayvakyt in Europe), is currently the only approved treatment for both advanced and indolent forms of the disease in the US and EU.
The deal also brings to Sanofi additional assets such as elenestinib, a next-generation treatment for systemic mastocytosis, and BLU-808, an investigational oral KIT inhibitor with potential across a broad range of immunological diseases.
Sanofi highlighted that Blueprint’s established relationships with allergists, dermatologists, and immunologists will complement its existing network and enhance its growing immunology pipeline.
This acquisition follows several recent deals by Sanofi to expand its research and development portfolio. In May, the company acquired Vigil Neuroscience for $470 million, and in January 2024, it finalized a $2.2 billion acquisition of biotech firm Inhibrx.
While Sanofi’s share price remained largely unchanged following the announcement, the company emphasized it maintains significant financial flexibility for future acquisitions.
